Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun 9;4(6):1240-68.
doi: 10.3390/jcm4061240.

Alternative Donor Transplantation for Acute Myeloid Leukemia

Nelli Bejanyan  1 , Housam Haddad  2 , Claudio Brunstein  3
Affiliations
Review

Alternative Donor Transplantation for Acute Myeloid Leukemia

Nelli Bejanyan et al. J Clin Med. .

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for adult patients with acute myeloid leukemia (AML), but its use for consolidation therapy after first remission with induction chemotherapy used to be limited to younger patients and those with suitable donors. The median age of AML diagnosis is in the late 60s. With the introduction of reduced-intensity conditioning (RIC), many older adults are now eligible to receive allo-HCT, including those who are medically less fit to receive myeloablative conditioning. Furthermore, AML patients commonly have no human leukocyte antigen (HLA)-identical or medically suitable sibling donor available to proceed with allo-HCT. Technical advances in donor matching, suppression of alloreactivity, and supportive care have made it possible to use alternative donors, such as unrelated umbilical cord blood (UCB) and partially HLA-matched related (haploidentical) donors. Outcomes after alternative donor allo-HCT are now approaching the outcomes observed for conventional allo-HCT with matched related and unrelated donors. Thus, with both UCB and haploidentical donors available, lack of donor should rarely be a limiting factor in offering an allo-HCT to adults with AML.

Keywords: AML; Haploidentical; Transplantation; UCB; alternative donor.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Grewal S.S., Barker J.N., Davies S.M., Wagner J.E. Unrelated donor hematopoietic cell transplantation: Marrow or umbilical cord blood? Blood. 2003;101:4233–4244. doi: 10.1182/blood-2002-08-2510. - DOI - PubMed
    1. Confer D., Robinett P. The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 2008;42(Suppl. 1):S3–S5. doi: 10.1038/bmt.2008.102. - DOI - PubMed
    1. Ballen K.K., Spitzer T.R., Yeap B.Y., McAfee S., Dey B.R., Attar E., Haspel R., Kao G., Liney D., Alyea E., et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol. Blood Marrow Transplant. 2007;13:82–89. doi: 10.1016/j.bbmt.2006.08.041. - DOI - PMC - PubMed
    1. Brunstein C.G., Barker J.N., Weisdorf D.J., DeFor T.E., Miller J.S., Blazar B.R., McGlave P.B., Wagner J.E. Umbilical cord blood transplantation after nonmyeloablative conditioning: Impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007;110:3064–3070. doi: 10.1182/blood-2007-04-067215. - DOI - PMC - PubMed
    1. Gladstone D.E., Zachary A.A., Fuchs E.J., Luznik L., Kasamon Y.L., King K.E., Brodsky R.A., Jones R.J., Leffell M.S. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol. Blood Marrow Transplant. 2013;19:647–652. doi: 10.1016/j.bbmt.2013.01.016. - DOI - PMC - PubMed

LinkOut - more resources